DLH Holdings Corp

DLH Holdings Corp(DLHC)股票分析

$4.310

-0.035 (-0.81%)收盘时

Loading chart…
High
4.340
Open
4.340
VWAP
4.33
Vol
4.14K
Mkt Cap
152.43M
Low
4.340
Amount
17.91K
EV/EBITDA, TTM
151.98

DLH Holdings Corp. is a provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies. The Company is focused on improved deployment of health and defense initiatives for multiple agencies within the federal government, including the Department of Health and Human Services and Department of Defense. Its digital transformation and cyber security solutions include tools, such as artificial intelligence and machine learning, cloud enablement, cybersecurity ecosystem, big data analytics, and modeling and simulation. The Company's science research and development solutions include data analytics, testing and evaluation, clinical trials research services, and epidemiology studies. Its systems engineering and integration solutions include system modernization, modeling, simulation & training, technology-enabled health solutions, software development, and robotics and unmanned systems.

AI analysis of DLH Holdings Corp (DLHC)

hold

DLH Holdings Corp is not a strong buy right now due to significant financial losses and declining revenue, with a current price of $4.4 and a forward P/E of 17.45, suggesting that while the stock is undervalued, the risks are substantial. The company reported a net income loss of $16.79 million in Q3 2026, which raises concerns about its financial health.

Analyst Ratings (2)

+132.02% upside
Buy
2 Buy
0 Hold
0 Sell
Current: 4.31
最低
10.00
平均
10.00
最高
10.00

Noble Capital

2026-07-31

目标价

$7

Outperform

Noble Capital

2025-05-09

目标价

$10

Outperform

估值指标

The current forward P/E ratio for DLH Holdings Corp (DLHC) is 17.45, compared to its 5-year average forward P/E of 8.90.

Forward P/E

Fair
5Y Average P/E
8.90
Current P/E
17.45
高估
34.52
低估
-16.72

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
10.49
Current EV/EBITDA
151.98
高估
29.69
低估
-8.72

Forward P/S

Fair
5Y Average P/S
0.42
Current P/S
0.36
高估
0.55
低估
0.28

Alphio AI Price Scenarios for DLHC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%DLHC

$5.55

情景价格

B

Base

Base · 50%DLHC

$4.96

情景价格

B

Bear

Bear · 25%DLHC

$4.16

情景价格

事件时间线

2026-06-30 (ET)

16:30:00

DLH Holdings Appoints Kathryn JohnBull as New CEO

2026-06-25 (ET)

16:30:00

DLH Holdings Awarded U.S. Navy Logistics IT Contract Worth $250M

2026-06-04 (ET)

17:10:00

DLH Holdings Files New Shelf Registration Statement

16:20:00

DLH Holdings Files $100M Mixed Securities Shelf

2025-12-10 (ET)

16:20:00

DLH Reports Q4 Revenue of $81.2M, Down 15.5% YoY

资讯

DLHC FAQ — answered by Alphio AI

DLH Holdings Corp. is a provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies. The Company is focused on improved deployment of health and defense initiatives for multiple agencies within the federal government, including the Department of Health and Human Services and Department of Defense. Its digital transformation and cyber security solutions include tools, such as artificial intelligence and machine learning, cloud enablement, cybersecurity ecosystem, big data analytics, and modeling and simulation. The Company's science research and development solutions include data analytics, testing and evaluation, clinical trials research services, and epidemiology studies. Its systems engineering and integration solutions include system modernization, modeling, simulation & training, technology-enabled health solutions, software development, and robotics and unmanned systems. It operates in the Technology sector (SERVICES-HELP SUPPLY SERVICES industry).

DLH Holdings Corp is not a strong buy right now due to significant financial losses and declining revenue, with a current price of $4.4 and a forward P/E of 17.45, suggesting that while the stock is undervalued, the risks are substantial. The company reported a net income loss of $16.79 million in Q3 2026, which raises concerns about its financial health.

2 analysts cover DLHC: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始